Status:

COMPLETED

TC-5214 as add-on the Treatment of Major Depressive Disorder

Lead Sponsor:

Targacept Inc.

Conditions:

Major Depressive Disorder

Depression

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

This is a multi-center, double blind, randomized, placebo-controlled, parallel group, flexible dose titration study conducted in centers in the USA and India. Following a washout period, subject will ...

Detailed Description

This is a multi-center, double blind, randomized, placebo-controlled, parallel group, flexible dose titration study conducted in centers in the USA and India. Following a washout period, subject will...

Eligibility Criteria

Inclusion

  • Diagnosis of major depressive disorder (MDD) according to DSM-IV and confirmed via MINI diagnostic scale
  • No more than 1 prior antidepressant course of treatment before trial entry.
  • Able to give written informed consent.
  • MADRS score greater than 27.
  • CGI-S score greater than or equal to 4.
  • No clinically significant abnormality on physical examination, vital signs, ECG or laboratory tests at screening.
  • Women of child bearing potential must: a) have a negative urine pregnancy test, b) not be nursing, and c) be willing to use acceptable methods of contraception throughout the study period.

Exclusion

  • Any co morbid psychiatric illness confirmed by MINI diagnostic scale, especially bipolar disorder, schizophrenia, dementia, or PTSD
  • Subjects with significant suicidal risk upon clinical assessment utilizing the M.I.N.I.
  • History of alcohol or drug abuse over the last 6 months
  • History of seizures or seizure disorders
  • Any other severe progressive and uncontrolled medical condition
  • For other controlled medical conditions, medication to be unchanged over the 2 months preceding screening, or else the subject will be excluded
  • Subjects with Glaucoma, Kidney Disease or Heart Disease
  • Known hypersensitivity to mecamylamine
  • Other investigational drug in previous 30 days
  • Screening QTcB or QTcF \> 450 msec
  • Current or prior citalopram treatment

Key Trial Info

Start Date :

June 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2009

Estimated Enrollment :

574 Patients enrolled

Trial Details

Trial ID

NCT00692445

Start Date

June 1 2008

End Date

July 1 2009

Last Update

June 21 2013

Active Locations (27)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 7 (27 locations)

1

Aurora Clinical Trials

Miami, Florida, United States, 33143

2

Community Research

Cincinnati, Ohio, United States, 45227

3

UT Southwestern Medical Center

Dallas, Texas, United States, 75390

4

Sravani Poly Clinic and Mental Health

Guntur, Andhra Pradesh, India, Guntur-522001